CFO
RARE icon

CVA Family Office’s Ultragenyx Pharmaceutical RARE Stock Holding History

CVA Family Office’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14
Closed -$509 – 1336
2025
Q2 		$509 Buy
+14
New +$505 ﹤0.01% 1230
2022
Q4 		– Sell
-50
Closed -$2K – 996
2022
Q3 		$2K Hold
50
– – ﹤0.01% 814
2022
Q2 		$3K Buy
+50
New +$3.08K ﹤0.01% 806
2022
Q1 		– Sell
-10
Closed -$1K – 985
2021
Q4 		$1K Buy
+10
New +$814 ﹤0.01% 885

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CVA Family Office's RARE Position: Q3 2025 in Review

CVA Family Office sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 14 shares — an estimated $509 sold.

CVA Family Office first reported a position in RARE in Q4 2021 and held it in 4 quarters. The position peaked at $3K in Q2 2022. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • CVA Family Office reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • CVA Family Office sold 14 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $509.
  • CVA Family Office first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and held it in 4 quarters.
  • CVA Family Office's Ultragenyx Pharmaceutical position peaked at $3K in Q2 2022.
  • 302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on CVA Family Office's 13F filing for Q3 2025, filed 30 Oct 2025.